Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.
Sector:
Commercial Services
Industry:
Miscellaneous Commercial Services
Employees:
2
Frequently Asked Questions
What is Market Cap of Virpax Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Virpax Pharmaceuticals Inc market cap is $13,295.00.
What is the 52-week high for Virpax Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Virpax Pharmaceuticals Inc 52 week high is $11.75 as of February 12, 2026.
What is Virpax Pharmaceuticals Inc stock price today?
Virpax Pharmaceuticals Inc stock price today is $0.0107.
What was Virpax Pharmaceuticals Inc stock price yesterday?
Virpax Pharmaceuticals Inc stock price yesterday was $0.0111.
What is the Price-to-Book ratio of Virpax Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Virpax Pharmaceuticals Inc P/B ratio is -0.007.
What is the 50-day moving average of Virpax Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Virpax Pharmaceuticals Inc 50-day moving average is $0.0158.
How many employees does Virpax Pharmaceuticals Inc have?